ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

Dexamethasone Improved Survival Of Leukemia

November 26, 2004

Radiation Oncology To Become Crowded, ACR Warns Physicians

December 15, 1995

Clinical Trials Approved By NCI

January 30, 2004

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

BioMedicines Begins Kidney Cancer Study; EntreMed Moves Forward.

February 25, 2000

ACS Board To Consider Proposal For Implementing Cancer Response System Nationwide; Could End CIS

June 7, 1985